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The orexin system regulates feeding, nutrient metabolism and energy homeostasis. Acute
pharmacological blockade of orexin receptor 1 (OXR-1) in rodents induces satiety and
reduces normal and palatable food intake. Genetic OXR-1 deletion in mice improves
hyperglycemia under high-fat (HF) diet conditions. Here we investigated the effects of
chronic treatment with the novel selective OXR-1 antagonist ACT-335827 in a rat model
of diet-induced obesity (DIO) associated with metabolic syndrome (MetS). Rats were
fed either standard chow (SC) or a cafeteria (CAF) diet comprised of intermittent human
snacks and a constant free choice between a HF/sweet (HF/S) diet and SC for 13 weeks.
Thereafter the SC group was treated with vehicle (for 4 weeks) and the CAF group was
divided into a vehicle and an ACT-335827 treatment group. Energy and water intake,
food preference, and indicators of MetS (abdominal obesity, glucose homeostasis, plasma
lipids, and blood pressure) were monitored. Hippocampus-dependent memory, which can
be impaired by DIO, was assessed. CAF diet fed rats treated with ACT-335827 consumed
less of the HF/S diet and more of the SC, but did not change their snack or total kcal
intake compared to vehicle-treated rats. ACT-335827 increased water intake and the
high-density lipoprotein associated cholesterol proportion of total circulating cholesterol.
ACT-335827 slightly increased body weight gain (4% vs. controls) and feed efficiency in
the absence of hyperphagia. These effects were not associated with significant changes
in the elevated fasting glucose and triglyceride (TG) plasma levels, glucose intolerance,
elevated blood pressure, and adiposity due to CAF diet consumption. Neither CAF diet
consumption alone nor ACT-335827 affected memory. In conclusion, the main metabolic
characteristics associated with DIO and MetS in rats remained unaffected by chronic
ACT-335827 treatment, suggesting that pharmacological OXR-1 blockade has minimal
impact in this model.
Keywords: diet-induced obesity, metabolic syndrome, food intake, orexin, orexin receptor antagonist, ACT-335827,
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INTRODUCTION
Metabolic syndrome (MetS) represents a group of risk fac-
tors for diabetes and cardiovascular disease; it is characterized
by abdominal obesity plus two of four factors including: ele-
vated circulating triglyceride (TG) levels, reduced circulating
high density lipoprotein-associated cholesterol (HDLc) levels,
elevated blood pressure, and elevated fasting plasma glucose
levels (International Diabetes Federation; http://www.idf.org).
Diet-induced obesity (DIO), which is a major causative fac-
tor of MetS, can also result in cognitive impairments and in
poorer hippocampus-dependent memory function (Eskelinen
et al., 2008; Francis and Stevenson, 2011). The current pri-
mary intervention for MetS is to lower body weight through
reduced energy consumption, a change of diet composition,
and increased physical activity (De Flines and Scheen, 2010).
Pharmacological treatments are expected to additionally help
patients to restrict over-eating by reducing systemic and brain
signals responsible for driving high caloric palatable food intake
(Adamo and Tesson, 2008).
Orexin neuropeptides A and B modulate energy balance and
metabolic homeostasis (Sakurai, 2006) but also palatable food
and sweet reward perception (Di Sebastiano and Coolen, 2012).
Orexins are expressed by a discrete number of neurons in the
lateral hypothalamus (De Lecea et al., 1998; Sakurai et al.,
1998) and their effects are mediated by the G-protein-coupled
orexin receptors type 1 and 2. OXRs are expressed widely in
orexinergic projection areas throughout the brain including the
mesolimbic system, implicated in reward/aversion, and includ-
ing several mid- and hindbrain regions, implicated in regulat-
ing energy homeostasis and food intake (Trivedi et al., 1998;
Marcus et al., 2001). For instance, some orexin neurons project
to the ventral tegmental area (VTA), where they synapse with
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dopaminergic and GABAergic neurons (Balcita-Pedicino and
Sesack, 2007); other orexin neurons innervate neuropeptide Y
and pro-opiomelanocortin expressing neurons of the arcuate
nucleus (Niimi et al., 2001; Tsuneki et al., 2010). Orexin neurons
also receive multiple afferent input (Yoshida et al., 2006) from
cortico-limbic regions, involved in either positive or negative
emotional processing, as well as from local hypothalamic areas,
involved in defense reactions, in autonomic and in circadian
regulation (Furudono et al., 2006); in addition, orexin neuron
activation is modulated by the anorectic adipokine leptin, by the
orectic peptide ghrelin, by circulating non-essential amino acids,
and by falling glucose levels (Yamanaka et al., 2003; Williams
et al., 2008; Louis et al., 2010; Karnani and Burdakov, 2011).
OXR mRNA or protein is also found in the periphery includ-
ing enteric neurons, stomach, pancreas, adrenal gland, and white
and brown adipose tissue (Kirchgessner and Liu, 1999; Blanco
et al., 2002; Digby et al., 2006; Adeghate et al., 2010; Skrzypski
et al., 2011). The relative functional significance of orexins in
controlling energy homeostasis and food intake by acting both
in the brain and periphery (Heinonen et al., 2008) has remained
elusive but orexin peptide or OXR levels appear to be regulated
under a variety of nutritional conditions such as food depri-
vation, sweetener-induced overconsumption and genetic obesity
(Mondal et al., 1999; Karteris et al., 2005; Furudono et al., 2006).
The preferential OXR-1 antagonist SB-334867 has been
described to reduce normal food intake in rats during the dark
phase (Haynes et al., 2000) by decreasing meal size (Parise et al.,
2011) and enhancing satiety onset (Ishii et al., 2005). In addition
to impacting quantitative natural feeding the OXR-1 may play a
key role in mediating the hedonic component of nutrient intake.
SB-334867 centrally injected in the VTA of rats inhibited feeding
stimulated by intra-nucleus accumbens injections of a mu-opioid
receptor agonist (Zheng et al., 2007). The systemic administra-
tion of SB-334867 reduced the overconsumption of a HF diet in
satiated rats (Choi et al., 2010), and another OXR-1 antagonist,
GSK1059865, reduced the binge-like intake of a HF/S diet (Piccoli
et al., 2012). Chronic administration of a high dose of SB-334867
to ob/ob female mice lacking leptin reduced food intake and
weight gain (Haynes et al., 2002), and this effect was associated
with improvements in glucose homeostasis. Contrarily, OXR-1
deficient mice became similarly obese to wild-type mice when
challenged with a HF diet (Funato et al., 2009). However, con-
sistent with the reported effects of chronic SB-334867 treatment,
fasting blood glucose and serum insulin levels were improved
in obese OXR-1 deficient mice (Funato et al., 2009). Finally,
a series of studies exploring SB-334867 in operant responding
models also suggest that blocking OXR-1 signaling can reduce
the motivation to consume HF/S foods (Borgland et al., 2009;
Choi et al., 2010; Cason and Aston-Jones, 2013). Central infu-
sion of the OXR-2 specific agonist [Ala11,D-Leu15]Orexin-B over
a period of 14 days decreased consumption of a HF diet and
reduced DIO (Funato et al., 2009). Genetically elevating brain lev-
els of orexins also prevented DIO by decreasing food intake and
stimulating energy expenditure through a mechanism requiring
OXR-2. Therefore, either blocking OXR-1 or activating OXR-2
signaling may provide benefits under conditions of prolonged
access to high palatable food that will lead to DIO.
The purpose of our study was to test the effects of the novel
OXR-1 antagonist ACT-335827 (Steiner et al., 2013) in a rat
model of DIO associated with MetS. In comparison to the fre-
quently used OXR-1 antagonist SB-334867, which may also bind
to other neuronal receptors (Gotter et al., 2012; Morairty et al.,
2012), ACT-335827 shows greater selectivity among a panel of
more than 100 neuronal targets [it only binds to the melatonin
MT1 receptor with greater than 50% (i.e., 58%) inhibition at
10µM; (Steiner et al., 2013)]. Affinity of ACT-335827, measured
by an intracellular calcium release assay, at the recombinant rat
OXR-1 was between 7 and 25 nM (depending on incubation time)
and between 630 and 1030 nM at the OXR-2. The calculated free
brain concentration in Wistar rats after oral gavage of 300mg/kg
was between 97 nM at 1 h and 166 nM at 6 h following admin-
istration. Accordingly, the oral dose of 300mg/kg was effective
in reducing a number of anxiety and stress-related measures in
the rat including autonomic activation, schedule-induced poly-
dipsia, and fear-potentiated startle; similar to dual OXR antag-
onists (Steiner et al., 2012). However, in contrast to dual OXR
antagonists, ACT-335827 did not simultaneously induce sleep or
hypolocomotion at 300mg/kg, likely because it did not block
OXR-2 at his dose (Steiner et al., 2013).
In the present study MetS was induced in rats exposed
to a CAF diet with constant access and free choice between
HF/S diet or SC. In addition, highly caloric human snacks
were provided 4 times weekly. Once metabolic disturbances
were established (13 weeks), rats were treated daily before the
onset of the dark phase with 300mg/kg of ACT-335827 or
vehicle for 4 weeks. The effects of chronic ACT-335827 treat-
ment were monitored on energy and water intake, food pref-
erence, abdominal obesity, glucose homeostasis, plasma lipid
levels, and blood pressure. Hippocampus-dependent cognitive
function, which has been shown to be impaired in rodents
exposed to DIO (Hwang et al., 2010; Davidson et al., 2012),
was also assessed in parallel using a contextual fear-conditioning
paradigm.
MATERIALS AND METHODS
ANIMALS
Thirty male Wistar rats (Harlan, Horst, NL) weighing 160–180 g
(6–7 weeks old) were single-housed upon arrival and accli-
mated to the Actelion animal facility under a regular 12 h
light/dark cycle (lights on at 6:00) for 2 weeks. During this
time they were fed SC [Diet 2018S: 18% kcal fat, 24%
kcal protein, 58% kcal carbohydrate (CHO) and 3.1 kcal/g;
Harlan Teklad Diets, Madison, WI, USA] ad libitum. All
experimental procedures were performed in strict accordance
with the relevant licenses issued by the Basel-Land Veterinary
office and adhered to Swiss federal regulations on animal
experimentation.
DIETS
After acclimatization, rats were randomly divided into two
groups. One group of 10 rats (250–325 g; 8–9 weeks old) con-
tinued to receive SC ad libitum and served as the control group
for the effects of CAF diet feeding. A second group of 20 rats
(275–320 g) was given a CAF diet comprised of a free choice
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between SC and a HF/S diet (Diet 2126: 47% kcal fat, 19.5%
kcal protein, 33.5% kcal CHO and 4.6 kcal/g; Provimi Kliba,
Kaiseraugst, Switzerland), both provided ad libitum. The CAF
diet group also received a human snack food 4 days per week of
15 kcal (weeks 1–5 of diet exposure), 30 kcal (weeks 6–13 of diet
exposure), or ad libitum for 1 h at the beginning of the dark phase
(weeks 14 to 18 of diet exposure). Seven types of snacks were pro-
vided (see Supplementary Table 1). One snack type was given per
day and they were alternated between sweet and savory. The inclu-
sion of human snacks, which are both highly caloric and high in
sugar, fat, and salt, can be an important addition to rodent models
of DIO, since voluntary over-snacking by humans may potenti-
ate obesity, as well as glycemic and cardiovascular abnormalities
(Kimokoti and Brown, 2011; Sampey et al., 2011).
EXPERIMENTAL DESIGN
Please see Figure 1 for a schematic outline of the experimental
design.
Both groups of animals (SC or CAF fed) were maintained on
their respective diets for 13 weeks and their body weights were
monitored once weekly. Blood glucose and plasma lipids levels
were determined at the end of week 11, after a 16 h fast, and at the
beginning of week 13, after a 6–8 h fast, respectively.
Chronic ACT-335827 or vehicle treatment began in week 14
of diet exposure. The CAF-diet fed rats were evenly assigned
to a vehicle (CAF-Veh, n = 11) or an ACT-335827 (CAF-ACT,
n = 9) treatment group based on their fasting blood glucose
levels obtained in week 11. All SC fed rats received vehicle treat-
ment only (SC-Veh, n = 10). ACT-335827 or vehicle was orally
administered daily, 2 h before the onset of the dark phase. Body
weights were recorded in the afternoon before the start of treat-
ment and once weekly thereafter. Food and water intake in the
home cages were continuously measured by an automated system
(Phenomaster, TSE systems, Bad Hamburg, Germany).
In week 3 of treatment (week 16 of diet exposure), rats were
tested in a contextual fear conditioning (CFC) paradigm. At the
beginning of week 4 of treatment (week 17 of diet exposure),
blood pressure of the rats was measured in the morning. At the
end of the same week, the rats were food deprived (16 h) before
an oral glucose tolerance test (oGTT) in the morning. At the
beginning of week 18 of diet exposure, the rats were sacrificed by
decapitation 24 h after the last ACT-335827 administration and
following a mild food deprivation (4–6 h).
DRUGS
ACT-335827 hydrobromide (Actelion Pharmaceuticals Ltd.,
Switzerland) was freshly prepared in 10% polyethylene glycol
400/0.5% methylcellulose in water, which served as vehicle (Veh).
It was administered orally at 300mg/kg based on the weight of
the free base, in a volume of 5mL/kg, and administered daily 2 h
before the onset of the dark phase.
The 300mg/kg dose was chosen based on the pharmacokinet-
ics of this compound, which were outlined in the Introduction.
At this dose, calculated free brain concentrations (>97 nM) were
sufficient to allow a significant blockade of OXR-1 (affinity at
the rat receptor: 7–25 nM, depending on the assay), without yet
blocking the OXR-2 (affinity: 630–1030 nM). This was confirmed
by the pharmacological actions of this compound, i.e., reduc-
ing stress-related outcomes without inducing sleep at this dose.
Following oral administration of ACT-335827 at 300mg/kg, cal-
culated free brain concentrations were rising from 1 h (97 nM) to
6 h (166 nM), and declined thereafter (1 nM at 24 h). Rats con-
sumed the majority of their food during the active, dark phase,
and they increased their eating pattern just before the switch of
the light-dark cycle. Thus, the rats were treated 2 h before onset
of the dark phase, and also the snacks (the most caloric type of
food used in this experiment) were provided at the beginning
of the dark phase, in order to assure that the large majority of
food intake during this chronic study would take place under full
blockade of the OXR-1.
FASTING BLOOD GLUCOSE AND PLASMA LIPID ANALYSIS BEFORE
CHRONIC DRUG TREATMENT
In week 11 of diet exposure, rats were fasted overnight (16 h).
Using gentle restraint, a tail blood sample was obtained and
FIGURE 1 | Schematic overview of the experimental setup. Rats were
maintained on standard chow (SC; n = 10) or cafeteria diet (CAF; n = 20) for 13
weeks (W). The CAF diet was comprised of a free choice between SC and a
high fat/sweet diet, both provided at libitum, and intermittent additional access
to human snacks. During these 13 weeks body weight (BW) was measured
weekly and blood glucose (BG) and plasma lipid (PL) concentrations were
assessed in week 11 and 13, respectively. Chronic vehicle (Veh) or ACT-335827
treatment (ACT; 300mg/kg, p.o., once daily before onset of the dark phase)
started in week 14. All SC fed rats received vehicle treatment only (SC-Veh;
n = 10). The CAF diet fed rats were divided into a vehicle (CAF-Veh; n = 11) and
an ACT-335827 (CAF-ACT; n = 9) treatment group based on an even distribution
of their blood glucose and plasma triglyceride levels, measured in week 11 and
13.Duringweeks 14–17 the food andwater intake and the bodyweight gainwas
assessed, and the feed conversion efficiency calculated. In week 16 cognitive
hippocampal function was assessed using a contextual fear paradigm. In week
17 blood pressure (BP) measurements and an oral glucose tolerance test
(oGTT) were performed. In the beginning of week 18 all rats were sacrificed.
Their plasma lipid (PL) and plasma leptin levels were assessed and the weight
of white adipose tissue deposits (WATs) and the interscapular brown adipose
tissue (iBAT) deposit was measured. See the Methods for further details.
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glucose levels were determined using a Glucometer (ACCU-
CHEK, Roche Diagnostics, Germany). For plasma lipid analysis
in week 13, rats were mildly fasted (6–8 h) and blood samples
were obtained by sublingual vein puncture under isoflurane anes-
thesia, divided between EDTA or heparin containing microtainer
tubes, and kept on ice. Plasma was collected by centrifugation
(2400 × g for 10min at 4◦C), placed in pre-chilled tubes and
stored at −20◦C. Levels of non-esterified fatty acid (NEFA),
total cholesterol, and TG were assayed in plasma from EDTA-
mixed blood, whereas HDL-cholesterol (HDLc) was quantified in
plasma from heparinized blood. All lipids were measured using
commercial enzyme assay kits and a fully automated analyzer
(Beckman Coulter AU480, Nyon, Switzerland).
CONTEXTUAL FEAR CONDITIONING (CFC)
A single-training trial CFC paradigmwas used to assess the effects
of the CAF diet in combination with ACT-335827 treatment
on hippocampus-dependent learning addressing simple contex-
tual memory. For the training of conditioned fear, rats were
singly placed in lit transparent plastic boxes (27 × 27 × 40 cm)
equipped with stainless steel grid shock floors within an enclosed
cubicle (Ugo Basile, Comerio, Italy) for 5min. A 1mA footshook
was then delivered for 2 s. After 2min the rats were returned to
their home cages. 24 h later, rats were re-exposed to the same
box for a 10min testing phase. Freezing behavior (defined as
absence of all movements except breathing) was measured using
an automated video-tracking system (Anymaze; Stoelting Co.,
Wood Dale, IL, USA).
BLOOD PRESSURE
Blood pressure was indirectly measured by blood volume pres-
sure recording (VPR) from the tail using the CODA 8-channel
high throughput non-invasive blood pressure system (EMKA
Technologies, Paris, France). Animals were pre-warmed at 37◦C.
They were then placed in restraining tubes and body temperature
was maintained using a heating pad. An occlusion tail-cuff was
inserted at the base of the tail and a transducer was placed 1 cm
below. Rats underwent 7 cycles of measurements, lasting ∼5min,
before they were returned to their home cage. Following man-
ual reviewing, at least 3 of the 7 measurements derived from
clearly defined and smooth VPRs were selected for further anal-
ysis. Based on this criteria, two CAF diet fed rats treated with
ACT-335827, and one CAF diet fed rat treated with vehicle, were
excluded from analyses. The systolic and diastolic blood pressures
were derived by taking the mean of the 3 selected values. The
mean blood pressure was calculated using the following formula:
(systolic pressure - diastolic pressure)/3 + diastolic pressure.
ORAL GLUCOSE TOLERANCE TEST (oGTT)
An oGTT was performed between 8:00 and 12:00 at the end of the
fourth week of treatment (week 17 of diet exposure) on overnight
fasted rats (16 h). In the morning, tail vein blood was collected
from rats of all treatment groups in random order for determina-
tion of fasting glucose levels (as described above). Approximately
30min later, a freshly prepared solution of glucose (2 g/kg/5mL
in water) was orally administered to the rats in a staggered man-
ner, and blood was again collected for glucose quantification 30,
60, 120, and 180min following oral glucose administration.
TISSUE AND BLOOD COLLECTION AT SACRIFICE
Eighteen to Twenty hours after the last ACT-335827 or vehicle
administration, rats were mildly fasted for 4–6 h before sacri-
fice by decapitation. Trunk blood was collected, divided between
EDTA- and heparin- containing tubes, and kept on ice for ∼2 h
before centrifugation. Plasma was collected into pre-chilled tubes
and stored at −20◦C for lipid quantification (as described above)
or at −80◦C for leptin analysis by a commercially available lep-
tin detection assay (Mesoscale, Gaithersburg, USA). Epididymal,
abdominopelvic, and mesenteric white adipose tissues (WATs),
as well as intrascapular brown adipose tissue (iBAT) were then
rapidly isolated and weighed.
STATISTICAL ANALYSIS
For each rat, food intake in grams was converted to energy
intake in kcal. For the time course analysis of energy and water
intake and diet preference, kcal values or water volumes (mL)
were cumulated over either 48 h or weekly. Body weight gain was
expressed as the percentage change from baseline weight at the
start of diet exposure or from the beginning of chronic treat-
ment. The area under the curve (AUC) of the time course of
blood glucose changes for each rat during the oGTT was calcu-
lated using the trapezoid rule. The weekly feed efficiency of each
rat was determined by normalizing body weight gain to the total
kcal intake of a given week.
For all measures, mean values and standard errors of the
mean (s.e.m.) were calculated per treatment/diet group. Before
the beginning of chronic treatment, the blood glucose and plasma
TG levels of the CAF diet groups were compared to each other and
to those of the SC fed group using unpaired two-tailed t-tests,
except for diet preference and weight gain, which was analyzed
using a Two-Way analysis of variance (ANOVA). Following the
start of chronic vehicle or ACT-335827 treatment, for all readouts
the effects of CAF diet feeding per se were determined by compar-
ing CAF diet fed vehicle treated rats with SC fed vehicle treated
rats using unpaired t-tests or Two-Way ANOVAs. The effects of
ACT-335827 were also determined for all readouts by compar-
ing vehicle-treated and ACT-335827-treated CAF fed rats using
unpaired t-tests, and Two-Way or Three-Way ANOVAs where
appropriate. CAF fed ACT-335827-treated rats were not com-
pared to SC-fed vehicle-treated rats. Post-hoc mean comparisons
were made using Tukey or Bonferroni tests. All statistical anal-
yses were performed using GraphPad Prism 5.03 or Statistica
(version 9) software, and statistical significance was accepted at
p < 0.05.
RESULTS
PROFILE OF DIET GROUPS BEFORE TREATMENT ONSET
Over the 13 weeks of diet exposure, the body weight gain of CAF
diet fed rats was significantly greater than that of SC fed rats
[Diet: F(1, 28) = 12.20, p < 0.05; Time × Diet: F(12, 336) = 3.42,
p < 0.05; Figure 2A]. Post-hoc analyses revealed significant group
differences in weeks 8, 12, and 13 of diet exposure (Figure 2A).
Fasting glucose levels of CAF diet fed rats were significantly
elevated at week 11 when compared to SC fed rats [t(30) = 2.3,
p < 0.05]. This parameter was used to divide CAF diet fed rats
in two subgroups with a similar mean and distribution of glucose
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FIGURE 2 | Weight gain, MetS and food intake before treatment
onset. (A) Time course of body weight gain over 13 weeks of SC
and CAF diet feeding. Body weight gain is expressed as the
percentage change from baseline body weight at the start of diet
exposure. Mean ± s.e.m. (SC n = 10; CAF n = 20). ∗p < 0.05 vs. SC
at the indicated time point by post-hoc test following ANOVA. Levels
of whole blood glucose (B), and of plasma triglycerides (TG) (C) were
analyzed in week 11 and 13, respectively. The group of 20 CAF diet
fed rats was subdivided into one Veh (n = 11) and one ACT (n = 9)
group which were going to start receiving treatment (Veh and ACT
indicated in brackets) in week 14. Horizontal bars represent the mean
± s.e.m. ∗p < 0.05 by t-test. (D) Energy intake and food preference
cumulated over 48 h before the start of Veh or ACT treatment. No
snack was given during this 48 h period. All three groups consumed a
similar amount of kcal. Both of the CAF diet fed groups preferred the
HF/S diet over the SC and they did not differ statistically in their
level of preference. Mean + s.e.m. (n = 9–11) per group. (SC,
standard chow; CAF, cafeteria diet; HF/S, high fat/sweet; Veh, vehicle;
ACT, ACT-335827).
levels (Figure 2B) that were then assigned to receive either vehi-
cle or ACT-335827 upon the start of treatment in week 14. Both
subgroups showed similar significantly elevated fasting glucose
levels compared to SC fed rats [CAF(Veh) vs. SC: t(19) = 2.14,
p < 0.05; CAF(ACT) vs. SC: t(17) = 2.39, p < 0.05; CAF(Veh) vs.
CAF(ACT): t(18) = 0.11, p = 0.91].
At week 13 of diet exposure plasma TG levels were also
found elevated in both groups fed a CAF diet as compared
to SC [CAF(Veh) vs. SC: t(19) = 3.18, p < 0.01; CAF(ACT) vs.
SC: t(17) = 2.18, p < 0.05] (Figure 2C). TG levels did not differ
between the CAF diet fed groups [t(18) = 0.57, p = 0.56]. Plasma
levels of NEFA, total cholesterol, HDLc, or the proportion of
HDLc in total cholesterol were not elevated in CAF diet fed rats
compared to SC diet fed rats (data not shown).
Finally, before the start of chronic drug treatment in week 14,
a 48 h assessment of the total energy intake of the HF/S diet and
SC on days when no snacks were presented (Figure 2D) was per-
formed. The two groups of rats exposed to the CAF diet and the
rats fed SC did not differ in their total kcal intake. With respect
to food choice, both of the CAF diet fed groups consumed signif-
icantly more of the HF/S diet (77.3% of total calories) than SC
(22.7% of total calories) [Food: F(1, 18) = 53.11, p < 0.05], but
they did not differ in their level of preference [CAF diet treat-
ment Group × Food: F(1, 18) = 1.97, p = 0.18]. With respect to
water intake, the three groups of rats did not significantly differ
(Supplementary Figure 1A).
In summary, rats fed the CAF diet gained more weight and
showed elevated fasting blood glucose and plasma TG levels com-
pared to rats fed SC. Forty-eight hours before the onset of chronic
ACT-335827 or vehicle administration, the two CAF diet fed
groups did not differ from each other in their total kcal and water
intake and in their preference of the HF/S diet over SC.
ACT-335827 REDUCES THE PREFERENCE FOR A HF/S DIET WITHOUT
AFFECTING WEEKLY TOTAL ENERGY INTAKE, AND INCREASES BODY
WEIGHT GAIN AND FEED CONVERSION EFFICIENCY
In general, all three experimental groups slightly reduced their
total energy intake over the 4 weeks of vehicle or ACT-335827
treatment [SC-Veh vs. CAF-Veh: Time: F(3, 57) = 17.2, p <
0.05; CAF-Veh vs. CAF-ACT: Time: F(3, 34) = 21.57, p < 0.05;
Figure 3A]. Vehicle treated rats fed a CAF diet did not differ in
their weekly total kcal intake compared to vehicle treated rats fed
SC [Diet: F(1, 19) = 3.13, p = 0.09; Diet × Time: F(3, 57) = 0.26,
p = 0.85]. Chronic administration of ACT-335827 did not affect
the total kcal intake of the CAF diet compared to vehicle treat-
ment [Treatment: F(1, 18) = 0.001, p = 0.98; Treatment × Time:
F(3, 54) = 0.92, p = 0.44]. Both vehicle and ACT-335827 treated
rats fed the CAF diet consumed significantly more of the HF/S
diet than SC or snack [Food: F(2, 36) = 157.4, p < 0.05]. Analysis
of the contribution of each food type to the total kcal intake
averaged over 4 weeks of vehicle treatment revealed that the rats
obtained in average 74% of their total kcal from the HF/S diet,
18% from SC, and 8% from snacks. Rats chronically treated
with ACT-335827 reduced their preference for the HF/S diet over
SC [Treatment × Food: F(2, 36) = 8.22, p < 0.05], irrespective of
week of treatment [Treatment × Food × Time: F(6, 108) = 0.13,
p = 1.28].
More detailed analyses of the weekly energy intake of each
food type separately over the 4 weeks of treatment revealed that
ACT-335827 significantly increased the intake of SC as com-
pared to vehicle [Treatment: F(1, 18) = 11.24, p < 0.05], and this
effect became stronger over time [Treatment × Time: F(3, 54) =
3.08, p < 0.05; Figure 3B]. Indeed, post-hoc comparisons showed
that ACT-335827 treatment significantly increased SC intake in
weeks 3 and 4. Conversely, ACT-335827 treatment significantly
decreased the intake of the HF/S diet as compared to vehi-
cle [Treatment: F(1, 18) = 7.47, p < 0.05], irrespective of week
of treatment [Treatment × Time: F(3, 54) = 0.742, p = 0.53;
Figure 3C]. Finally, both the vehicle and ACT-335827 treated
rats consumed a similar amount of the snack food over the 4
weeks of treatment [Treatment: F(3, 54) = 1.38, p = 0.26; Time:
F(3, 54) = 2.66, p = 0.06; Treatment × Time: F(3, 54) = 1.38, p =
0.25; Figure 3D].
Vehicle treated CAF diet fed rats and SC fed rats did not dif-
fer in their weight gain over the 4 weeks of treatment [Time:
F(4, 19) = 14.91, p < 0.05;Diet × Time: F(1, 76) = 0.48, p = 0.74;
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FIGURE 3 | Effect of diet and chronic ACT-335827 treatment on feeding
behavior, body weight, and feed efficiency. (A) Total energy intake divided
into SC, HF/S diet, and snack intake cumulated weekly. CAF-diet fed Rats
chronically treated with ACT-335827 reduced their preference for the HF/S
diet over SC. Snack intake was not affected by ACT-335827. For further
statistical analyses see Results. (B–D) Energy intake of SC, HF/S diet, and
snack expressed as the percentage of the total energy intake and cumulated
in 1 week time bins over the 4 weeks (weeks 14–17) of Veh or ACT
treatment. Significant differences between groups were revealed only for the
SC intake, not for the HF/S diet or snack intake. ∗p < 0.05 vs. CAF-Veh at the
indicated time points by post-hoc test following ANOVA. (E) Body weight
gain expressed as a percentage change from baseline (BL) weight (i.e., at
start of chronic treatment). CAF-Veh and SC-Veh groups did not statistically
differ from each other. ∗p < 0.05 vs. CAF-Veh at the indicated time points by
post-hoc test following ANOVA. (F) Weekly efficiency of conversion of total
kcal intake into body weight gain. No significant differences were revealed
between the SC-Veh and CAF-Veh groups. Mean ± s.e.m. (n = 9–11) per
group. ∗p < 0.05 vs. CAF-Veh at the indicated time points by post-hoc test
following ANOVA. Note that throughout this manuscript SC-Veh is always
compared to CAF-Veh, and CAF-ACT is always compared to CAF-Veh. No
comparisons between CAF-ACT and SC-Veh were made. (SC, standard chow;
CAF, cafeteria diet; Veh, vehicle; ACT, ACT-335827; HF /S, high fat/sweet).
Figure 3E]. In the CAF diet fed groups, chronic ACT-335827
treatment significantly increased weight gain over 4 weeks com-
pared to vehicle treatment [Treatment: F(1, 18) = 6.29, p < 0.05;
Treatment × Time: F(4, 72) = 5.42, p < 0.05]. Post-hoc analysis
revealed that this increase was due to significantly greater weight
gains by the ACT-335827 treated rats in weeks 3 and 4.
Normalization of weekly energy intake to absolute body weight
revealed that CAF diet fed rats treated with vehicle were not
hyperphagic compared to SC fed rats or to ACT-335827 treated
rats over the 4 weeks of treatment (data not shown). However,
examination of the efficiency of feed conversion into body weight
gain of vehicle treated CAF diet fed and SC fed rats revealed a
significant reduction for both groups over 4 weeks of treatment
from a positive efficiency to a negative efficiency [Time: F(3, 19) =
21.9, p < 0.05], but no effect of diet and no diet × time inter-
action [Diet: F(1, 19) = 0.07, p = 0.80; Diet × Time: F(3, 57) =
1.88, p = 0.14; Figure 3F]. Similarly, both groups of CAF fed
rats showed decreasing feed efficiency over the 4 weeks of treat-
ment [Time: F(3, 19) = 22.4, p < 0.05]. However, ACT-335827
treatment inhibited this decrease compared to vehicle treatment
[Treatment: F(1, 19) = 5.00, p < 0.05], which was more pro-
nounced during the first 3 weeks [Treatment × Time: F(3, 54) =
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2.65, p = 0.06] and reached significance in week 3 (p < 0.05;
post-hoc test).
In summary, rats consuming a CAF diet and chronically
treated with ACT-335827 slightly decreased their preference for
a HF/S diet over SC without changing their weekly total kcal
intake and snack consumption. CAF diet fed rats treated with
ACT-335827 gained significantly more weight over 4 weeks com-
pared to vehicle treatment, likely due to increased feed conversion
efficiency.
ACT-335827 INCREASES WATER INTAKE IN CAF DIET FED RATS
Similar to the total food intake, overall water intake slightly
decreased over the 4 weeks of treatment with vehicle or
ACT-335827 independent of diet [SC-Veh vs. CAF-Veh:
Time: F(3, 57) = 18.91, p < 0.05; CAF-Veh vs. CAF-ACT:
Time: F(3, 54) = 11.3, p < 0.05; Supplementary Figure 1B].
Furthermore, vehicle treated rats fed CAF diet drank significantly
less water than vehicle treated rats fed only SC, independent
of week of treatment [Diet: F(1, 19) = 10.95, p < 0.05; Diet ×
Time: F(3, 57) = 0.03, p = 0.93]. In CAF fed rats, ACT-335827
treatment significantly increased water intake compared to
vehicle treatment, largely irrespective of the week of admin-
istration [Treatment: F(1, 18) = 12.39, p < 0.05; Treatment ×
Time: F(3, 54) = 2.38, p = 0.08]. The effect reached statistical
significance in the second and third week of treatment (p < 0.05;
post-hoc test).
NO DETECTABLE EMOTIONAL OR COGNITIVE IMPAIRMENTS DUE TO
CAF DIET EXPOSURE ALONE OR IN COMBINATIONWITH CHRONIC
ACT-335827 TREATMENT
Consumption of energy rich diets high in fat and/or sugar has
been shown to impair learning and memory, particularly through
their effects on hippocampal function. A CFC task was performed
after 3 weeks of chronic ACT-335827 or vehicle treatment (17
weeks following the onset of CAF diet exposure).
During the fear conditioning training the rats of all groups
responded with a similar amount of freezing over the 2min fol-
lowing the presentation of a 1mA foot shock (data not shown).
When returned to the aversive conditioned context 24 h later,
vehicle treated CAF-fed rats displayed a high level of freezing
(∼70%) over the entire 10min of testing that was similar to that
of both the vehicle treated rats fed SC [t(19) = 0.37, p = 0.72] and
the ACT335827 treated rats fed a CAF diet [t(18) = 0.61, p = 0.55;
Figure 4].
CAF DIET-INDUCED GLUCOSE INTOLERANCE IS NOT AFFECTED BY
ACT-335827 TREATMENT
The effect of CAF diet exposure alone and in combination with
ACT-335827 treatment on glucose homeostasis and tolerance
were assessed. Following a 16 h fast, the blood glucose levels of
vehicle-treated CAF fed rats were slightly elevated from those of
SC fed vehicle treated rats, but the difference was not significant
[t(18) = 0.77, p = 0.45; Figure 5A]. In addition, ACT-335827
treatment of rats fed a CAF diet did not alter fasting glucose levels
compared to vehicle treatment [t(18) = 1.91, p = 0.07].
Upon oral glucose challenge, blood glucose levels were sig-
nificantly elevated in vehicle treated CAF fed rats compared to
FIGURE 4 | Effect of CAF diet and ACT-335827 on cognition in week 16.
Percentage of time spent freezing over a 10min test of contextual
conditioned fear. Mean ± s.e.m. (n = 9–11 per group). No statistical
difference between groups was revealed. (SC, standard chow; CAF,
cafeteria diet; Veh, vehicle; ACT, ACT-335827).
FIGURE 5 | Glucose homeostasis in week 17. (A) Oral glucose tolerance
test (oGTT) performed on overnight fasted SC and CAF fed rats treated with
Veh or ACT. Whole blood glucose was measured before (0min) and at the
indicated time points after the oral (po) administration of 2mg/kg glucose
(arrow). ∗p < 0.05 vs. CAF-Veh at the indicated time point by post-hoc test
following ANOVA. Mean ± s.e.m. (n = 8–11) per group. Due to an
incomplete blood sample set, data from one SC-Veh and one CAF-Veh rat
had to be omitted because of repeated measures within subjects analyses.
(B) AUC calculated individually for each rat. ∗p < 0.05 by t-test. The
CAF-ACT group was statistically not different from the CAF-Veh group. (SC,
standard chow; CAF, cafeteria diet; Veh, vehicle; ACT, ACT-335827; po, per
os; AUC, area under the curve; ns, not significant).
SC fed rats [Diet: F(2, 25) = 9.85, p < 0.05; Figure 5A], but the
shape of the time course up to 180min after challenge was not
affected [Diet × Time: F(8, 100) = 1.33, p = 0.24]. Post-hoc anal-
yses revealed that the effect was most pronounced at the glucose
peak (60min after challenge), which was significantly higher in
CAF fed rats than in SC fed rats. Analysis of the AUCglucose con-
firmed the glucose intolerance of the CAF-fed rats compared to
SC-fed rats [t(18) = 2.72, p < 0.05]. Chronic ACT-335827 treat-
ment in combination with CAF diet feeding showed a trend
to impair glucose tolerance but did not significantly alter the
levels or time course of blood glucose elevations upon chal-
lenge [Treatment: F(1, 17) = 4.28, p = 0.054; Treatment × Time:
F(4, 68) = 0.23, p = 0.92; Figure 5B], or the AUCglucose [t(17) =
1.80, p = 0.09].
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CAF DIET-INDUCED ELEVATION IN BLOOD PRESSURE IS NOT ALTERED
BY CHRONIC ACT-335827 TREATMENT
Hypertension is correlated with central obesity and is an aspect
of MetS. Compared to vehicle treated rats fed a SC diet, vehicle
treated rats consuming a CAF diet for 17 weeks had signifi-
cantly elevated diastolic [t(18) = 2.16, p < 0.05], systolic [t(18) =
2.53, p < 0.05], and mean blood pressure [t(18) = 2.37, p < 0.05;
Figure 6]. Chronic ACT-335827 treatment did not affect the
elevation in blood pressure due to CAF diet feeding.
ACT-335827 DOES NOT AFFECT ELEVATIONS IN WAT AND iBAT MASS
DUE TO A CAF DIET
Elevations in visceral white adipose tissue mass are associated
with central obesity and are an indicator of MetS. The main
visceral fat deposits in male rodents are the epididymal depot,
the adominopelvic depot, and the mesenteric depot. At the time
of sacrifice, following 4 weeks of chronic vehicle treatment, CAF
diet fed rats had significantly heavier epididymal [t(19) = 2.43,
p < 0.05; Figure 7A] and adominopelvic [t(19) = 2.13, p < 0.05;
Figure 7B], but not mesenteric (Figure 7C) fat deposits, than SC
fed rats. Moreover, the proportion of body weight represented by
the combined mass of all three visceral fat deposits was signifi-
cantly higher in vehicle treated rats fed a CAF diet compared to
those fed SC [t(19) = 2.36, p < 0.05; Figure 7D]. In addition to
WAT, the CAF diet fed rats treated with vehicle also had signifi-
cantly larger deposits of iBAT compared to vehicle treated SC fed
rats [t(19) = 3.0, p < 0.05; Figure 7E]. Chronic treatment with
ACT-335827 did not significantly alter the elevations in visceral
WAT depots and iBAT mass resulting from CAF diet feeding as
compared to vehicle treatment.
ACT-335827 INCREASES THE PROPORTION OF PLASMA HDLc LEVELS,
BUT DOES NOT ALTER ELEVATED PLASMA TG LEVELS DUE TO
A CAF DIET
Plasma markers of MetS include reduced levels of HDLc and
elevated TG levels. At the time of sacrifice following 4 weeks
of vehicle or ACT-335827 treatment (and 18 weeks of diet
exposure), plasma levels of HDLc (Figure 8A), total cholesterol
FIGURE 6 | Blood pressure in week 17. Diastolic, systolic, and mean blood
pressures of SC or CAF diet fed rats treated with Veh or ACT. Horizontal
bars represent the mean ± s.e.m. (n = 7–10) per group. Reliable data was
not attainable from 1 CAF-Veh rat and from 2 CAF-ACT rats, and were
therefore omitted from analyses. ∗p < 0.05 by t-test. No statistical
difference was revealed between the CAF-ACT and the CAF-Veh group. (SC,
standard chow; CAF, cafeteria diet; Veh, vehicle; ACT, ACT-335827).
(Figure 8B), or the proportion of HDLc relative to total choles-
terol (Figure 8C) were not different between vehicle treated rats
fed CAF diet or SC. However, plasma TG levels were significantly
higher in vehicle treated CAF diet fed rats compared to SC fed
rats [t(18) = 2.70, p < 0.05; Figure 8D]. As expected from eleva-
tions in WAT and iBAT mass due to CAF diet feeding reported
above, plasma levels of leptin were significantly elevated in these
rats compared to SC fed rats [t(18) = 2.72, p < 0.05; Figure 8E].
Finally, plasma levels of NEFA did not differ significantly between
vehicle treated rats fed SC or CAF (Figure 8F).
ACT-335827 treatment of CAF diet fed rats did not sig-
nificantly affect plasma levels of TG [t(18) = 0.61, p = 0.55],
cholesterol, NEFA, Plasma HDLc or leptin compared to vehi-
cle treatment. However, the proportion of HDLc in the total
plasma cholesterol was found significantly elevated [t(18) = 3.84,
p < 0.05; Figure 8C].
DISCUSSION
CAF DIET FEEDING AS A MODEL OF MetS
In humans, over-consumption of palatable food rich in fat,
sugar, and salt facilitates MetS development. Under a CAF diet
comprised of a choice between a HF/S diet and SC and an
additional snack 4 times weekly, rats developed major signs of
human MetS, including abdominal adiposity, elevated TG and
fasting blood glucose levels, glucose intolerance, and elevated
blood pressure when compared to rats fed only SC. Conversely,
plasma levels of NEFA, total cholesterol, HDLc, and the ratio
between the latter two, were not altered. These findings are in
agreement with those of other DIO studies in rodents report-
ing a similar induction of partial abnormalities associated with
MetS in man [e.g., (Sampey et al., 2011)]. An impairment
of hippocampus-dependent memory function induced by DIO,
which might be a consequence of altered blood-brain barrier
integrity (Davidson et al., 2012) and/or a reduction of growth
factors and proteins responsible for synaptic plasticity (Woo
et al., 2013), has been demonstrated both in human and rodents
(Kanoski and Davidson, 2011). Still, hippocampus memory func-
tion, which was assessed in the present study by employing a
CFC paradigm, was not altered in rats fed a CAF diet com-
pared to rats fed SC. Using a one-trial conditioning protocol
and a shock intensity similar to ours, Hwang et al. showed
that male mice fed a normal diet responded with ∼50% freez-
ing during the 6min test of conditioned fear, whereas this was
reduced to ∼20% in mice fed a HF diet for 1 year (Hwang
et al., 2010). A CAF diet exposure of only 4 months as in our
studymay have been insufficient to cause learning impairments in
this test.
EFFECT OF CHRONIC ACT-335827 TREATMENT IN THE MetS MODEL
ACT-335827 treatment began in week 14 of CAF diet exposure,
a time point when rats displayed elevated fasting blood glucose
and plasma TG levels. Our results indicate that 4 weeks of ACT-
335827 treatment did not significantly alter metabolic abnormal-
ities and adiposity generated by CAF diet exposure alone, despite
the animals showing an improved diet composition due to a slight
but significant reduction in preference for the HF/S diet over
SC. This reduction in HF/S diet intake upon OXR-1 blockade is
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FIGURE 7 | Fat mass at sacrifice. The effect of SC or CAF diet exposure on
the mass of epididymal (A), abdominopelvic (B), and mesenteric (C) visceral
fat deposits in rats treated with Veh or ACT. (D) Normalization of cumulated
visceral fat mass (in A–C) to body weight (BW) per rat and expressed as a
percentage. (E) Mass of intrascapular brown adipose tissue (iBAT). Mean ±
s.e.m. (n = 9–11 per group). ∗p < 0.05 by t-test. No statistical difference was
revealed between the CAF-ACT and the CAF-Veh group. (SC, standard chow;
CAF, cafeteria diet; Veh, vehicle; ACT, ACT-335827; ns, not significant).
FIGURE 8 | Plasma lipids and leptin at sacrifice. Plasma levels of
HDL-cholesterol (HDLc) (A), total cholesterol (B), HDL-c levels (in A)
expressed as a percentage of total plasma cholesterol (in B) (C), triglyceride
(TG) levels (D), leptin (E), and non-esterified fatty acids (NEFA) (F), in rats fed
SC or a CAF diet and treated with Veh or ACT. Horizontal bars represent the
mean ± s.e.m. (n = 9–11 per group). ∗p < 0.05 by t-test. (SC, standard chow;
CAF, cafeteria diet; Veh, vehicle; ACT, ACT-335827; HDL, high density
lipoprotein; ns, not significant).
consistent with other studies in rats suggesting a role for OXR-
1 activation in positively regulating the motivation to consume
palatable foods (Zheng et al., 2007; Choi et al., 2010). A decrease
in reward perception under ACT-335827 treatment might also be
expected to decrease intake of highly palatable snacks. However,
consumption of the human snacks (presented for 1 h, 4 times
weekly), was not affected by the drug. ACT-335827 administra-
tion may thus, be ineffective at reducing the binge-like intake
of highly palatable foods under conditions, where either another
type of palatable food (the HF/S diet) is freely available, or where
no additional intermittent periods of stress or food-restriction
occur. Using the OXR-1 antagonist GSK1059865, Piccoli et al.
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showed that OXR-1 signaling is only involved in the binge-like
intake of highly palatable food if an additional specific stressor
component (e.g., smelling but no access to the palatable food) is
present (Piccoli et al., 2012).
The reduced overall food intake among all experimental
groups during weeks 3 and 4 of vehicle or ACT-335827 treatment
may be due to the performance of the CFC test to assess cognition
(in week 3), and a blood pressure analysis and an overnight period
of fasting before the oGTT (in week 4). These procedures were
likely a source of stress on the rats, which may have affected their
energy consumption and led to a slight decline of body weight
gain in week 4. It is unlikely that those procedures confounded
the overall conclusions of the current study with regard to OXR-1
blockade because all experimental groups (SC-Veh, CAF-Veh, and
CAF-ACT) were simultaneously affected. Moreover, the overall
pattern of the different diet consumption, which was displayed by
the different groups already in week 2 of chronic treatment (until
when no additional potentially stressful experimental procedures
had been performed) was actually maintained in weeks 3 and 4
as well (see Figure 3A). Whether the additional exposure to envi-
ronmental stressors during weeks 3 and 4 actually intensified the
preference of the CAF-ACT treated rats for consuming more of
the SC as compared to the CAF diet, cannot be excluded.
Despite affecting HF/S food preference vs. SC, ACT-335827
had no impact on total calorie intake because the decrease in
HF/S food intake was entirely compensated for by an increase in
SC intake. As a result, given that chronic ACT-335827 treatment
also increased body weight gain, feed efficiency was enhanced.
Although not directly tested, these results suggest that ACT-
335827 administration may reduce energy expenditure. Funato
et al. (2009) showed that energy expenditure is reduced in OXR-1
deficient mice under low fat, but not high fat, feeding con-
ditions. Conversely, ob/ob female mice showed even increased
energy expenditure under chronic treatment with SB-334867
administered at 30mg/kg (Haynes et al., 2002). The reason for
these discrepancies remains unclear, but biological compensa-
tion, phenotypically expressed in knockout animals, and sex or
species differences are likely explanations that can be consid-
ered. Moreover, the OXR-1 preferential antagonist SB-334867 has
recently been tested by two independent groups for selectivity
(Gotter et al., 2012; Morairty et al., 2012): these studies suggest
that at high doses as applied by Haynes et al. (2002), SB-334867
could additionally interact with a number of other brain targets.
Orexins also stimulate BAT thermogenesis, but the individ-
ual role played by the OXR-1 in modulating BAT function is
unclear (Haynes et al., 2002; Sellayah et al., 2011; Tupone et al.,
2011). BAT is important for plasma TG clearance, which improves
insulin resistance due to DIO (Bartelt et al., 2011). In the current
study the elevated weight gain and feed efficiency seen with ACT-
335827 treatment under CAF diet feeding was not associated with
an altered elevation in iBAT mass or a change in plasma TG lev-
els compared to vehicle treatment. This might suggest that BAT
was functioning normally in ACT-335827 treated rats challenged
with a CAF diet. However, UCP-1 levels, which serves as a marker
of BAT thermogenesis (Haynes et al., 2002; Sellayah et al., 2011),
were not analyzed to confirm this conclusion. An alternative pos-
sibility for the reduced energy expenditure is that ACT-335827
had an inhibitory effect on non-exercise activity thermogenesis,
which can be generated by orexin A (Novak et al., 2006; Novak
and Levine, 2009).
Interestingly, the elevated body weight gain and increased
feed efficiency seen over 4 weeks of ACT-335827 treatment were
not associated with an increase in visceral fat mass compared
to vehicle treatment. Thus, the weight gained by ACT-335827 -
treated-rats must have occurred in fat deposits not analyzed (e.g.,
subcutaneous) and/or in non-fat tissues. Blood pressure of CAF
diet fed rats also remained unchanged by treatment.
Rats exposed to a CAF diet for 13 weeks marginally consumed
less water than rats fed SC in the 48 h before vehicle or ACT-33527
treatment onset; this decrease became significant over the subse-
quent 4 weeks of vehicle administration. ACT-335827 treatment,
however, countered this decrease, even though acute administra-
tion of ACT-335827 to rats under normal feeding conditions does
not affect water intake during their active phase (Steiner et al.,
2013).
The mechanisms by which orexins modulate water balance
or glucose metabolism through OXR-1 and OXR-2 binding have
not been extensively investigated. Existing evidence suggests that
orexins induce glucose production in the liver (Yi et al., 2009) and
facilitate glucose uptake in skeletal muscle (Shiuchi et al., 2009).
In addition, orexins A and B have been shown to differentially
modulate glucagon release from pancreas (Goncz et al., 2008;
Adeghate and Hameed, 2011). The unaltered glucose homeosta-
sis observed with chronic ACT-335827 treatment in CAF diet fed
rats with existing glucose imbalance contrasts with the improved
fasting glucose levels seen in obese OXR-1 deficient mice (Funato
et al., 2009) and in ob/ob female mice chronically treated with a
high dose of the preferential OXR-1 antagonist SB-334867 before
obesity onset (Haynes et al., 2002). Again, developmental com-
pensation, species differences or non OXR-1 related effects may
be responsible for these discrepancies.
A final observation of our study was that CAF diet fed rats
chronically treated with ACT-335827 had elevated HDLc to total
cholesterol ratios. HDLc is cardioprotective due to its antioxi-
dant, anti-inflammatory, and scavenging properties (Mooradian
et al., 2008). HDLc has a complex metabolism, and elevated lev-
els must be interpreted in context with the overall lipid profile
(Mooradian et al., 2008). To our knowledge there has been no
reported involvement of the orexin system in HDLc processing;
the mechanism by which ACT-335827 affects HDLc metabolism
warrants further examination.
It is difficult to directly compare the results that we obtained
using ACT-335827 with previous investigations using other OXR-
1 antagonists, because this is the first study exploring chronic
pharmacological OXR-1 blockade in a rat model of DIO asso-
ciated with MetS. It also has to be mentioned that most of our
knowledge concerning the effects of OXR-1 inhibition on food
intake in rodents derives from using the OXR-1 antagonist SB-
334867, which at high dose is likely to affect additional neuronal
targets (Gotter et al., 2012; Morairty et al., 2012). Another newer
generationOXR-1 selective compound, GSK1059865, for instance
did not confirm previous findings using SB-334867 (Choi et al.,
2010) in the sense that GSK did not affect high palatable food
intake per se under no-stress and no food restriction conditions
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(Piccoli et al., 2012). Thus, it is desirable that future studies
exploring the role of OXR-1 signaling in feeding further will
employ not only SB-334867 but also other OXR-1 antagonists
from different chemical classes.
Taken together, utilizing a free choice nutrient regime with
additional human snacks as a model of DIO, this study was suc-
cessful in inducingmost aspects of humanmetabolic syndrome in
Wistar rats. Chronic ACT-335827 treatment for 4 weeks reduced
the preference for a high-fat/high-sweet diet compared to stan-
dard laboratory food pellets but had no effect on snack intake or
absolute energy intake. ACT-335827 even slightly increased body
weight gain. The main characteristics of human metabolic syn-
drome, including abdominal obesity, decreased glucose tolerance,
enhanced blood pressure, and increased TGs remained unaffected
by ACT-335827 treatment, at doses otherwise active in reducing
environmental stress-induced outcomes (Steiner et al., 2013). It
is concluded that continuous selective pharmacological blockade
of OXR-1, in brain and periphery, under the applied experimen-
tal conditions has minimal impact on rat net energy balance
resulting from food reward, nutrient metabolism, and physical
homeostasis.
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